Skip to main content
OpenTrials
Completed

NCT Number: NCT07516756

Effect of Collagen Peptides on Skin Health: A Clinical Trial

The goal of this clinical trial is to evaluate whether daily oral supplementation with 2.5 g of specific bioactive collagen peptides (SCP) can improve skin physiology in healthy adult women aged 35-55 years. The main questions it aims to answer are:

Does SCP supplementation increase skin hydration and barrier function? Does SCP improve skin elasticity, firmness, and collagen content? Does SCP reduce the appearance of periorbital wrinkles and improve overall skin appearance? Researchers will compare SCP supplementation to a placebo (a look-alike substance containing no collagen peptides) to see if SCP supports skin structure and appearance over eight weeks.

Participants will:

Consume one sachet of SCP or placebo daily for eight weeks Attend three study visits at baseline, week 4, and week 8 for facial imaging, instrumental skin measurements, and expert assessments Have objective measures taken, including skin hydration, transepidermal water loss, elasticity, firmness, dermal collagen content, and 3D wrinkle morphology Complete subjective skin assessments rated by trained evaluators using a visual analogue scale Report any adverse events or intolerance reactions at each visit This study is designed to provide an integrated evaluation of multiple skin parameters, including barrier function, biomechanical properties, dermal matrix composition, and wrinkle characteristics, in a single trial. By combining objective and subjective measures, the study aims to generate robust and clinically interpretable evidence for the effects of oral collagen peptide supplementation on skin health.

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Beijing EWISH Testing Technology Co., Ltd

Beijing, Haidan, 100142, China

About this study

This clinical trial investigates whether daily oral supplementation with specific bioactive collagen peptides (SCP) can support healthy skin in adult women. Skin aging is a natural process influenced by genetics, hormones, and lifestyle, leading to wrinkles, reduced elasticity, and changes in skin structure. Collagen is a key protein that helps maintain skin strength and elasticity, and its levels decline with age.

The study will evaluate the effects of an 8-week course of SCP supplementation compared to a placebo in healthy women aged 35-55 years. Researchers aim to determine whether oral collagen peptides can improve skin hydration, elasticity, firmness, and overall appearance. This trial combines multiple objective and subjective measures to provide a comprehensive assessment of skin health, offering insights into non-invasive nutritional strategies to maintain skin structure and appearance over time.

The findings from this study are expected to enhance understanding of how collagen peptides affect skin physiology and contribute to evidence-based recommendations for supporting healthy skin.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fitzpatrick skin type III-IV
  • Presence of crow's feet wrinkles graded 2-4
  • Presence of under-eye fine lines graded 2-5
  • Generally in good health
  • Able to comply with study procedures and visit schedule

Exclusion criteria

  • Use of systemic or topical anti-inflammatory medication, including corticosteroids, within the 4 weeks prior to baseline
  • Known hypersensitivity or allergy to any ingredient of the investigational products
  • Pregnancy, breastfeeding, or intention to become pregnant during the study period
  • History of relevant dermatological conditions: psoriasis, eczema, atopic dermatitis, or severe acne
  • Presence of birthmarks, hyperpigmentation, active inflammation, or other visible skin abnormalities in the test areas
  • Recent aesthetic procedures Use of anti-aging or topical treatments
  • Intake of nutritional supplements
  • Participation in other clinical studies within the past 2 months
  • Significant lifestyle or dietary changes during the study period
  • Excessive UV exposure
  • Systemic diseases, including heart, immune, vascular, liver, gallbladder, or kidney disorders
  • Known allergies to foods, cosmetics, skincare products, or topical medications
  • Any other condition that, in the investigator's opinion, would make the participant ineligible

Treatment and study plan

Placebo

Dietary Supplement

Participants in this arm receive a matching placebo sachet once daily for 8 weeks. The placebo contains plant-derived maltodextrin and is identical in appearance, taste, and texture to the collagen peptide supplement. It is dissolved in warm water and consumed orally. Participants continue their usual lifestyle habits while taking the placebo.

Specific Collagen Peptides

Dietary Supplement

Participants in this arm receive 2.5 g of specific bioactive collagen peptides (VERISOL®) once daily for 8 weeks. The powder is dissolved in warm water and consumed orally. The supplement contains defined collagen peptides derived from bovine type I collagen, which have been shown to support skin hydration, elasticity, firmness, dermal collagen content, and wrinkle reduction. Participants continue their usual lifestyle habits while taking the supplement.

Primary outcomes

  1. stratum corneum hydration (SCH)

    Time frame: From enrollment to the end of treatment at 8 weeks

    Stratum corneum hydration (SCH) measures the water content in the outermost layer of the skin, reflecting the skin's ability to retain moisture and maintain a healthy barrier. In this study, SCH is the primary efficacy endpoint, used to compare the effect of daily oral supplementation with specific bioactive collagen peptides (SCP) versus placebo over an 8-week period.

    SCH is assessed using a Corneometer CM825 at the cheek. Each site is measured six times, and the mean value is used for analysis. Higher SCH values indicate better skin hydration, whereas lower values suggest dryness or impaired barrier function. Changes in SCH over time are compared between the treatment and placebo groups to evaluate the impact of collagen peptide supplementation on skin hydration.

Secondary outcomes

  1. Transepidermal Water Loss (TEWL)

    Time frame: From enrollment to the end of treatment at 8 weeks

    TEWL measures the rate of water loss through the skin, indicating the integrity of the skin barrier. In this study, TEWL is assessed using the Tewameter TM 300 at the cheek in triplicate, with mean values used for analysis. Higher TEWL values suggest impaired barrier function, while lower values indicate better barrier integrity. Changes over the 8-week supplementation period are compared between the collagen peptide and placebo groups.

  2. Skin Elasticity (R2 and R5) and Firmness (F4)

    Time frame: From enrollment to the end of treatment at 8 weeks

    Skin elasticity and firmness are evaluated using the Cutometer MPA580, which applies controlled suction to assess the biomechanical properties of the cheek.

    R2 (gross elasticity): overall skin elasticity R5 (net elasticity): elastic recovery relative to total deformation F4 (firmness): resistance to deformation Measurements are performed in triplicate and averaged. These parameters provide insight into the skin's structural resilience and are compared between treatment and placebo groups over 8 weeks.

  3. Dermal collagen content

    Time frame: From enrollment to the end of treatment at 8 weeks

    Dermal collagen content is measured non-invasively using the SIAMETRICS SIAscope V at a 2 mm depth of the cheek. This device quantifies dermal chromophores, including collagen, to assess the integrity and composition of the dermal extracellular matrix. Changes over the 8-week intervention are compared between the SCP and placebo groups.

  4. Wrinkle Morphology

    Time frame: From enrollment to the end of treatment at 8 weeks

    Wrinkle characteristics around the eyes (area, volume, depth) are measured using the Derma TOP 3D imaging system.

  5. Skin Appearance (3D Imaging + VAS)

    Time frame: From enrollment to the end of treatment at 8 weeks

    Full-face 2D images are captured with VISIA-CR for additional objective assessments, including spots, skin tone, hydration, and elasticity.

    Subjective evaluations are performed using a Visual Analogue Scale (VAS) by three trained evaluators, assessing:

    Smoothness Glossiness Fineness Elasticity Crow's feet and under-eye fine lines VAS scores range from 0 to 10. Higher values indicate better outcomes for attributes such as smoothness, elasticity, and glossiness, while lower values reflect improvement in periorbital wrinkles. Changes over the 8-week supplementation period are compared between treatment and placebo groups.

Sponsors and collaborators

Lead sponsor

Collagen Research Institute

Industry

Collaborators

  • GELITA

Registry information

Official study title

Impact of Oral Supplementation of Specific Bioactive Collagen Peptides on Human Skin Physiology: A Randomized, Double-Blind, Placebo-Controlled Trial

Acronym: BCP-Skin

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Apr 8, 2026
Registry last updated
Apr 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.